RxDoctor Payments Data

Paul Gambino, MD

Family Medicine · Stuart, FLNPI 1235427451

Payments from drug & device makers

$155,658in general payments, 2019–2025

Across 1,197 payments — averaging $130.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$140K
  • AbbVie$2K
  • Lilly USA, LLC$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Pfizer$1K
  • plus $8K from 47 others

What the payments were for

  • Speaking & faculty fees$130,40084%
  • Travel & lodging$5,5024%
  • Food & beverage$19,73813%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$155,658 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$284,972
Medicare patients
350
Services billed
3,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab408$285,513
MounjaroTirzepatide119$161,217
OzempicSemaglutide77$123,957
JardianceEmpagliflozin72$94,400
EliquisApixaban57$41,769
FarxigaDapagliflozin Propanediol44$37,934
TrulicityDulaglutide22$33,191
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$23,115
Tresiba Flextouch U-200Insulin Degludec14$20,623
Praluent PenAlirocumab19$19,479
XareltoRivaroxaban13$19,029
KerendiaFinerenone19$16,537
Breo ElliptaFluticasone/Vilanterol32$10,945
MyrbetriqMirabegron26$5,980
Mesalamine12$5,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,636$194,408141 claims
Novo NordiskOzempic$1,501$123,95777 claims
Boehringer IngelheimJardiance$493$94,40072 claims
PfizerEliquis$1,062$41,76957 claims
AstraZenecaFarxiga$1,606$37,93444 claims
GSKTrelegy Ellipta, Breo Ellipta$949$34,06055 claims
Johnson & JohnsonXarelto$293$19,02913 claims
BayerKerendia$677$16,53719 claims
AbbVieSynthroid$1,809$2,08924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →